Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial
Дурвалумаб в комбинации с неоадъювантной химиотерапией при раннем тройном негативном раке молочной железы: долгосрочный анализ испытания GeparNuevo
2026-04-20
SCID: 54.1/jqm4byk7
Discuss with AI
DurvalumabGeparNuevo trialearly triple-negative breast cancerneoadjuvant chemotherapystromal tumor-infiltrating lymphocytes (sTILs)
Figures from the paper
Abstract (AI)
= 0.045). sTILs in residual disease (RD) could be assessed in 39/71 patients without pCR. Post hoc analyses by sTILs high (>10%) versus low (≤10%) in RD showed estimated 7-year iDFS rates of 92.3% (95% CI, 56.6 to 98.9) and 51.4% (95% CI, 29.2 to 69.7), respectively. Hence, adding durvalumab to dose-dense NACT without adjuvant continuation of checkpoint inhibition improved long-term survival outcomes, irrespective of the extent of pathologic response. This underscores the necessity to re-evaluate the adjuvant continuation of checkpoint inhibition.
Key Findings
1
Adding durvalumab to dose-dense neoadjuvant chemotherapy (NACT) improved long-term survival outcomes in early triple-negative breast cancer without adjuvant checkpoint inhibitor continuation.
2
Benefit of durvalumab was observed irrespective of the extent of pathologic response (pCR vs residual disease).
3
In patients with residual disease and low sTILs (≤10%), the estimated 7-year iDFS was 51.4% (95% CI, 29.2 to 69.7).
4
In patients with residual disease, high stromal tumor-infiltrating lymphocytes (sTILs >10%) were associated with an estimated 7-year iDFS of 92.3% (95% CI, 56.6 to 98.9).
5
Results suggest re-evaluating the practice of adjuvant continuation of checkpoint inhibition after neoadjuvant durvalumab plus NACT.
Research Object
Durvalumab combined with dose-dense neoadjuvant chemotherapy in patients with early triple-negative breast cancer enrolled in the GeparNuevo trial
Research Subject
Long-term survival outcomes (including invasive disease-free survival) and the impact of adding durvalumab without adjuvant continuation of checkpoint inhibition, stratified by pathologic response and stromal tumor-infiltrating lymphocytes in residual disease
Publication Details
Publication Date
2026-04-20
Journal
Publisher
ISSN
Cited by
4
Access Type
Author Information
Download PDF
Subscribe to digest